|
Lifesciences industry harnesses AI-powered automation to reduce bottlenecks & speed-up workflows
|
|
Nandita Vijayasimha, Bengaluru
August 25 , 2025
|
|
|
Lifesciences industry harnesses AI-powered automation to reduce bottlenecks and speed-up workflows. This is an emerging trend reshaping the pharmaceutical operations, enhancing compliance, efficiency, and innovation, stated Udith Vaidyanathan, co-founder and CEO, LogicFlo AI.
These technologies enable better cross-functional collaboration and visibility, allowing companies to respond more quickly to regulatory changes and market demands. It supports continuous improvement by minimising the time required from scientific experts, enabling them to dedicate more focus to complex, higher-order problem-solving.
Furthermore, adapting and integrating Agentic AI represents a forward-looking shift in the rapidly evolving life sciences industry. Allowing humans to leverage intelligent, autonomous support systems will amplify decision-making and accelerate outcomes. The concept is not about replacing humans but giving them advanced support that paves the way for breakthrough innovations and more agile, forward-thinking pharmaceutical operations, he added.
Noting that artificial intelligence (AI) evolved from a mere aspirational tool to become an indispensable backbone across industries, Udit said that it is now a trusted presence in boardrooms and labs alike, helping people work smarter, make decisions and fuel strategic clarity.
In the lifesciences sector, AI has matured from being a promising assistant in drug discovery to an essential partner across the spectrum, including regulatory compliance, documentation and research streamlining. In pharma, where every delay can ripple, AI-powered automation is emerging as a quiet game-changer. Unlike the rigid, rule-based systems, customised AI platforms are trained on domain-specific standard operating procedures (SOPs), clinical protocols, and global regulatory frameworks, including GxP and 21 CFR Part 11, Vaidyanathan told Pharmabiz in an email.
Modern AI platforms can generate well-structured content by drawing from existing documents and clinical data, all while adhering to industry guidelines. This enables medical writers to produce accurate, high-quality drafts with speed and consistency. As a result, researchers and scientific teams are now able to shift their focus toward more strategic and impactful work. These systems don’t just complete tasks; they understand context, follow compliance rules, and adapt to distinct workflows, he said.
Driven by this technological advancement, the pharmaceutical industry and the venture capitalists are increasingly confident in AI’s potential to improve operations and innovations. According to a 2025 Prosus report, $2.8 billion in global VC funding has already flowed into agentic AI, with healthcare and life sciences flagged as high-impact sectors. In parallel, international and national frameworks are speeding up the use of practical, risk-aware AI solutions. US FDA’s 2024 draft guidance on AI tools stresses the need for outputs that are traceable and easy to explain. In India, the ICMR’s 2023 ethical guidelines for medical AI emphasise the importance of safety, accountability, and auditable results.
Agentic AI isn’t about replacing scientific expertise; it’s about amplifying it. By taking over repetitive tasks, these systems free up researchers to focus on thinking, innovation, and patient outcomes. It's no longer a futuristic concept in life sciences, but the co-author of today’s scientific narrative, quietly orchestrating efficiency and precision. They work alongside human experts and shape the very trajectory of scientific progress, he said.
In fact, for LogicFlo, founded just last year, AI has already secured multiple commercial customers, including major multi-year contracts with a Fortune 500 pharmaceutical companies. This contract spans over 300 teams and 10,000 users globally, across US, Europe, India, and South East Asia. By streamlining complex workflows in medical affairs, regulatory, quality, and promotional content, our company is enabling expert teams to shift their focus from administrative tasks to high-impact innovation, Vaidyanathan said.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|